• Explore /
  • Poster
  • / The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.

The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.

Abstract Video & Slides Poster

Authors

Lorenza Mittempergher

Lorenza Mittempergher

Research and Development, Agendia NV, Amsterdam, Netherlands

Lorenza Mittempergher , Midas M. Kuilman , Andrei Barcaru , Benjamin Nota , Leonie J.M.J. Delahaye , M. William Audeh , Denise M. Wolf , Christina Yau , Lamorna Brown Swigart , Gillian L. Hirst , W. Fraser Fraser Symmans , Ruixiao Lu , Minetta C. Liu , Rita Nanda , Laura Esserman , Laura van 't Veer , Annuska M. Glas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 514)

DOI

10.1200/JCO.2022.40.16_suppl.514

Abstract #

514

Poster Bd #

286

Abstract Disclosures

Similar Posters

First Author: Timothy Jay Price

First Author: Sara M. Tolaney

First Author: Sara M. Tolaney

First Author: Benjamin Philip Levy